Article révisé par les pairs
Titre:
  • Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
Auteur:Azambuja, Evandro; Bedard, Philippe L; Suter, T.; Piccart-Gebhart, Martine
Informations sur la publication:Targeted oncology, 4, 2, page (77-88)
Statut de publication:Publié, 2009-04
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Anti-HER-2 therapies
Breast cancer
Cardiotoxicity
Lapatinib
Trastuzumab
MeSH keywords:Adjuvants, Immunologic -- administration & dosage
Anthracyclines -- administration & dosage
Antibodies, Monoclonal -- administration & dosage
Antibodies, Monoclonal -- adverse effects
Breast Neoplasms -- immunology
Breast Neoplasms -- mortality
Breast Neoplasms -- pathology
Breast Neoplasms -- physiopathology
Breast Neoplasms -- therapy
Drug Resistance, Neoplasm
Female
Heart Failure -- chemically induced
Humans
Oxidative Stress
Protein Kinase Inhibitors -- administration & dosage
Protein Kinase Inhibitors -- adverse effects
Quinazolines -- administration & dosage
Quinazolines -- adverse effects
Receptor, Epidermal Growth Factor -- antagonists & inhibitors
Receptor, erbB-2 -- antagonists & inhibitors
Receptor, erbB-2 -- immunology
Survival Rate
Ventricular Outflow Obstruction -- chemically induced
Note générale:Journal Article
Review
Langue:Anglais
Identificateurs:urn:issn:1776-260X
info:doi/10.1007/s11523-009-0112-2
info:scp/67349248085
info:pmid/19418111